Geron Plans to Present at Upcoming Investor Conferences
Get Alerts GERN Hot Sheet
Join SI Premium – FREE
FOSTER CITY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to present at the following investor conferences:
- Bank of America Securities 2026 Healthcare Conference
Presentation on Tuesday, May 12 at 4:35 p.m. ET in Las Vegas, NV
- 2026 Stifel Virtual Targeted Oncology Forum
Virtual presentation on Wednesday, May 20 at 12:00 p.m. ET
A live and archived audio webcast of the conference call will be available from the Investors and Media section of the Company’s website at www.geron.com.
About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.
Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
[email protected]
Source: Geron Corporation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Defiance ETFs Announces Temporary Trading Halt of the Defiance Daily 2X Space ETF (SPCL) on Cboe BZX Exchange, Inc.
- Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1
- Dr. Jose Jacob Scholarship for Future Doctors Opens 2027 Applications to Support the Next Generation of Physicians Across the United States
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Stifel, BofA/Merrill LynchSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share